Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03306420

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

Metastatic or Locally Advanced Unresectable Solid Tumors Clinical Trial

Official title:
Phase I, First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of MS201408-0005A as Single Agent and Sequentially in Combinations With MS201408-0005C or MS201408-0005B in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors

Clinical Trial Summary

This is a Phase I, open-label study to determine the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and preliminary antitumor activity of MS201408-0005A as single agent (Part IA only) and in combination with MS201408-0005C or MS201408-0005B (Part IB, Part IC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Metastatic or Locally Advanced Unresectable Solid Tumors
Clinical Trial Details
NCT number NCT03306420
Study type Interventional
Source EMD Serono
Contact
Status Terminated
Phase Phase 1
Start date October 3, 2017
Completion date January 14, 2019
View Details
See also
  Status Clinical Trial Phase
Terminated NCT05198349 - First in Human Study of M1069 in Advanced Solid Tumors Phase 1
Recruiting NCT05396833 - Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) Phase 1
Active, not recruiting NCT04170153 - Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) Phase 1